Hillsdale Investment Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Hillsdale Investment Management’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-427	Closed	-$130K	–	703
2018 Q4	$130K	Buy	+427	New	+$138K	0.02%	394
2018 Q3	–	Sell	-207	Closed	-$76K	–	563
2018 Q2	$76K	Buy	+207	New	+$73.7K	0.01%	303

Other funds holding EIGR

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Hillsdale Investment Management's EIGR Position: Q1 2019 in Review

Hillsdale Investment Management sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q1 2019, closing a stake of 427 shares — an estimated $130K sold.

Hillsdale Investment Management first reported a position in EIGR in Q2 2018 and held it in 2 quarters. The position peaked at $130K in Q4 2018. 63 funds tracked by Wall St. Rank hold EIGR as of Q1 2019.

Hillsdale Investment Management reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
Hillsdale Investment Management sold 427 Eiger BioPharmaceuticals, Inc. shares in Q1 2019, an estimated $130K.
Hillsdale Investment Management first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2018 and held it in 2 quarters.
Hillsdale Investment Management's Eiger BioPharmaceuticals, Inc. position peaked at $130K in Q4 2018.
63 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q1 2019.

Based on Hillsdale Investment Management's 13F filing for Q1 2019, filed 13 May 2019.